Do you want to read an article? Please log in or register.
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study
Inflammatory Bowel Disease
COMMENTED
Related content
Inflammatory Bowel Disease
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Lancet Gastroenterol Hepatol.
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group
doi: 10.1016/S2468-1253(19)30012-3.
Inflammatory Bowel Disease
Complicated disease and response to initial therapy predicts early surgery in paediatric Crohn's disease: results from the Porto Group GROWTH study
J Crohns Colitis.
Levine A, Chanchlani N, Ziv-Baran T, Escher JC, Amil Dias J, Veres G, Koletzko S, Turner D, Kolho KL, Paerregaard A, Staiano A, Lionetti P, Nuti F, Sladek M, Shaoul R, Lazowska-Prezeorek I, de Carpi JM, Sigall Boneh R, Pfeffer Gik T, Cohen-Dolev N, Russell RK, Porto Group of ESPGHAN
doi: 10.1093/ecco-jcc/jjz111.
Inflammatory Bowel Disease
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study
J Crohns Colitis
Ferrante M, Feagan BG, Panés J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, D'Haens GR
doi: 10.1093/ecco-jcc/jjab093
Inflammatory Bowel Disease
Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)": An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis
Z Gastroenterol.
Hüppe A, Langbrandtner J, Häuser W, Raspe H, Bokemeyer B
doi: 10.1055/a-0605-4080.
Inflammatory Bowel Disease
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
★ 2
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
Inflamm Bowel Dis
Sandborn WJ, Feagan BG, Danese S, O'Brien CD, Ott E, Marano C, Baker T, Zhou Y, Volger S, Tikhonov I, Gasink C, Sands BE, Ghosh S
doi: 10.1093/ibd/izaa236
Inflammatory Bowel Disease
Riboflavin supplementation in patients with Crohn's disease (RISE-UP study)
J Crohns Colitis.
von Martels JZH, Bourgonje AR, Klaassen MAY, Alkhalifah HAA, Sadaghian Sadabad M, Vich Vila A, Gacesa R, Gabriëls RY, Steinert RE, Jansen BH, Bulthuis MLC, van Dullemen HM, Visschedijk MC, Festen EAM, Weersma RK, de Vos P, van Goor H, Faber KN, Harmsen HJM, Dijkstra G
doi: 10.1093/ecco-jcc/jjz208.
Inflammatory Bowel Disease
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
Lancet Gastroenterol Hepatol.
Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G
doi: 10.1016/S2468-1253(20)30188-6.
Inflammatory Bowel Disease
Evaluation of Crohn's Disease Activity: Development of an Ultrasound Score in a Multicenter Study
Inflamm Bowel Dis.
Ripollés T, Poza J, Suarez Ferrer C, Martínez-Pérez MJ, Martín-Algíbez A, de Las Heras Paez B
doi: 10.1093/ibd/izaa134.
Inflammatory Bowel Disease
Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3
Inflamm Bowel Dis.
Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T
doi: 10.1093/ibd/izy384.